RadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
- Revenue
- +25.0%
- EPS
- −47.4%
- Free cash flow
- −43.2%
- Total debt
- +21.2%
Quarter to June 2026, against a year earlier
Follow RDNT
Alert me
RadNet, Inc. (RDNT) P/B ratio
As of 5 November 2026, RadNet, Inc. (RDNT) trades at a P/B ratio of 4.4×. Over the past ten years it has ranged from 1.3× (March 2020) to 60.4× (April 2015); the current reading is higher than 54% of that period. That is above the Diagnostics & Research industry median of 3.4× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 4.0× | (12.08%) |
| FY2024 | 4.5× | 66.59% |
| FY2023 | 2.7× | 26.53% |
| FY2022 | 2.1× | (53.24%) |
| FY2021 | 4.6× | 18.43% |
| FY2020 | 3.9× | (10.85%) |
| FY2019 | 4.3× | 77.01% |
| FY2018 | 2.4× | (63.74%) |
| FY2017 | 6.7× | 16.68% |
| FY2016 | 5.8× | (22.23%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 3.4× | 8.08% |
| Mar 2026 | 3.2× | (19.53%) |
| Dec 2025 | 4.0× | (10.18%) |
| Sep 2025 | 4.4× | 22.77% |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| VCYT Veracyte, Inc. compare | 1.4× |
| ICLR ICON PLC compare | 1.7× |
| GRAL GRAIL, Inc. compare | 2.4× |
| QGEN QIAGEN N.V. compare | 3.1× |
| RDNT RadNet, Inc. | 4.4× |
| SHC Sotera Health Company compare | 6.2× |
| CDNA CareDx, Inc. compare | 8.6× |
| BLLN BillionToOne, Inc. compare | 9.9× |
| ADPT Adaptive Biotechnologies Corporation compare | 23.5× |
| Diagnostics & Research industry median | 3.4× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on RDNT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement